Overview

A Phase II Study to Treat Advanced Malignant Glioma

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 for the treatment of Advanced Malignant Glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Dihydrotachysterol
Rilotumumab